Hema Now
In this episode of Hema Now, Giancarlo Castaman explores the evolution of haemostasis and haemophilia care, reflecting on how advances in understanding coagulation biology have transformed treatment strategies for patients with bleeding disorders. From the challenges of managing rare disorders and balancing bleeding and thrombosis risks, to the promise and limitations of gene therapy, this discussion highlights the innovations shaping the future of the field.
Spotify | Apple | Amazon Music | YouTube | Download MP3
In this episode of Hema Now, Giancarlo Castaman explores the evolution of haemostasis and haemophilia care, reflecting on how advances in understanding coagulation biology have transformed treatment strategies for patients with bleeding disorders. From the challenges of managing rare disorders and balancing bleeding and thrombosis risks, to the promise and limitations of gene therapy, this discussion highlights the innovations shaping the future of the field.
Timestamps:
00:00 – Introduction
01:34 – Origins in haemostasis research
02:49 – Haemophilia care through decades
05:40 – Challenges managing rare disorders
07:19 – Priorities leading haemostasis advancement
10:18 – Gene therapy future challenges
14:35 – International networks improving outcomes
16:40 – Balancing bleeding thrombosis risks
18:30 – Emerging therapies transforming haemophilia
21:03 – Future haemostasis research priorities
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
Disclosure: TBC
Keywords: Bleeding disorders, clotting factors, coagulation, emerging therapies, gene therapy, haematology, haemophilia, haemostasis, rare bleeding disorders, thrombosis.
